Cargando…

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (C(min)) associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minot-This, Marie-Sophie, Boudou-Rouquette, Pascaline, Jouinot, Anne, de Percin, Sixtine, Balakirouchenane, David, Khoudour, Nihel, Tlemsani, Camille, Chauvin, Jonathan, Thomas-Schoemann, Audrey, Goldwasser, François, Blanchet, Benoit, Alexandre, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231369/ https://www.ncbi.nlm.nih.gov/pubmed/35745797 http://dx.doi.org/10.3390/pharmaceutics14061224

Ejemplares similares

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
por: Tlemsani, Camille, et al.
Publicado: (2023)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
por: Velev, Maud, et al.
Publicado: (2021)

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
por: Barth, Claire, et al.
Publicado: (2020)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2021)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2012)

Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa
por: Millet, Aurélien, et al.
Publicado: (2021)

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study
por: Jouinot, Anne, et al.
Publicado: (2018)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years
por: Shido, Yoji, et al.
Publicado: (2017)

Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017)

Effect of Acid‐Suppressive Strategies on Pazopanib Efficacy in Patients With Soft‐Tissue Sarcoma
por: Pisano, Sorana G., et al.
Publicado: (2019)

Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
por: Alshamsan, Bader, et al.
Publicado: (2021)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
por: Kim, Sang Kyum, et al.
Publicado: (2021)

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
por: Hong, Jung Yong, et al.
Publicado: (2023)

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California
por: Seto, Tiffany, et al.
Publicado: (2019)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
por: Damotte, Diane, et al.
Publicado: (2019)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bjdqur3178t68016psrm9s9c60